In two separate reports utilizing different models of cancer cachexia, MyD88 deletion attenuated several measures of cachexia, including anorexia, muscle catabolism, fat loss, hypothalamic inflammation and fatigue [51,52]. This evidence concerns the gene MYD88 and cancer.